Table 3.
Estimated insulin sensitivity, AUa | Estimated insulin sensitivity, AUa,b | |||
---|---|---|---|---|
β (95% CI) | p-value | β (95% CI) | p-value | |
VAT adipocyte size | − 0.19 (− 0.31 to − 0.07) | 0.004 | − 0.14 (− 0.30 to 0.01) | 0.06 |
VAT PPAR-γ | 0.05 (− 0.57 to 0.67) | 0.88 | 0.03 (− 0.71 to 0.78) | 0.93 |
VAT FAS | 0.49 (− 0.02 to 1.00) | 0.06 | 0.10 (− 0.39 to 0.60) | 0.67 |
VAT SCD1 | 0.16 (− 1.06 to 1.37) | 0.79 | 0.23 (− 1.23 to 1.69) | 0.75 |
VAT HIF-1α | − 0.32 (− 0.67 to 0.03) | 0.07 | − 0.37 (− 0.66 to − 0.09) | 0.01 |
VAT VEGFA | 0.03 (− 0.27 to 0.32) | 0.86 | 0.03 (− 0.23 to 0.29) | 0.82 |
VAT ESR1 | 0.05 (− 0.38 to 0.48) | 0.80 | − 0.09 (− 0.48 to 0.31) | 0.65 |
VAT AdipoQ | 0.06 (− 0.24 to 0.36) | 0.69 | 0.06 (− 0.21 to 0.34) | 0.63 |
VAT CD163+ cells | − 0.37 (− 1.01 to 0.28) | 0.25 | 0.05 (− 0.67 to 0.77) | 0.89 |
VAT CD68+ cells | 0.25 (− 0.06 to 0.57) | 0.11 | 0.24 (− 0.04 to 0.52) | 0.09 |
VAT CD3+ cells | − 0.31 (− 0.84 to 0.22) | 0.24 | − 0.21 (− 0.71 to 0.28) | 0.38 |
VAT CD20+ cells | − 0.33 (− 0.69 to 0.04) | 0.08 | − 0.17 (− 0.56 to 0.23) | 0.39 |
VAT PcF | − 0.46 (− 0.82 to − 0.1) | 0.02 | − 0.36 (− 0.72 to 0.01) | 0.06 |
VAT IL-6 mRNA | − 0.52 (− 0.96 to − 0.09) | 0.02 | − 0.34 (− 0.81 to 0.14) | 0.16 |
VAT IL-18 mRNA | − 0.17 (− 0.35 to 0.01) | 0.07 | − 0.13 (− 0.29 to 0.04) | 0.13 |
VAT TNF-α mRNA | − 0.35 (− 0.67 to − 0.03) | 0.03 | − 0.27 (− 0.57 to 0.04) | 0.08 |
VAT MCP-1 mRNA | − 0.22 (− 0.59 to 0.15) | 0.20 | − 0.25 (− 0.47 to − 0.03) | 0.03 |
VAT visceral adipose tissue, AU arbitrary units, PPAR Peroxisome proliferator activated receptor, FAS fatty-acid synthase, SCD Stearoyl-CoA desaturase, HIF Hypoxia-inducible factor, VEGFA vascular endothelial growth factor, ESR1 estrogen receptor 1, AdipoQ adiponectin, CD cluster of differentiation, PcF pericellular fibrosis, IL interleukin, TNF tumor necrosis factor, MCP Monocyte Chemoattractant Protein. N = 25.
aEstimated insulin sensitivity calculated through Composite Matsuda Index.
bModel corrected for VAT mass.